Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Ernexa Therapeutics Inc. (ERNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.68% for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-03-11
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-09-30 was 1.39%, a 50.71% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-06-30 was 1.82%, a 36.81% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-09-30 was 2.82%, a 27.03% increase year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-06-30 was 2.88%, a 78.88% increase year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 1.68%, a 41.46% decline from fiscal 2018.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.87%, a 45.69% increase from fiscal 2017.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 1.97%, a 64.17% increase from fiscal 2016.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.20%, a 0.00% change from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2019-12-31 | 1.68% 10-K · filed 2021-03-11 | |||
| 2019-09-30 | 1.39% 10-Q · filed 2020-11-13 | 1.70% 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | 1.82% 10-Q · filed 2019-08-12 | 1.82% 10-Q · filed 2019-08-12 | ||
| 2018-12-31 | 2.87% 10-K · filed 2020-03-19 | |||
| 2018-09-30 | 2.82% 10-Q · filed 2019-11-01 | 2.87% 10-Q · filed 2019-11-01 | ||
| 2018-06-30 | 2.88% 10-Q · filed 2019-08-12 | 2.88% 10-Q · filed 2019-08-12 | ||
| 2017-12-31 | 1.97% 10-K · filed 2019-03-22 | |||
| 2017-09-30 | 2.22% 10-Q · filed 2018-11-09 | 1.77% 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | 1.61% 10-Q · filed 2018-08-06 | 1.62% 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | 1.63% 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | 1.20% 10-K · filed 2018-03-09 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-08 | 1.20% 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | 1.16% 10-Q · filed 2017-08-04 | 1.20% 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | 1.26% 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | 1.20% 10-K · filed 2017-03-09 | |||
| 2015-09-30 | 1.27% 10-Q · filed 2016-11-09 | 1.18% 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 1.19% 10-Q · filed 2016-08-04 | 1.18% 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 1.17% 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 1.38% 10-K · filed 2016-03-15 | |||
| 2014-09-30 | 1.42% 10-Q · filed 2015-11-09 | 1.37% 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | 1.26% 10-Q · filed 2015-08-10 | 1.25% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 1.24% 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | 0.60% 10-K · filed 2015-03-27 | |||
| 2013-09-30 | 1.00% 10-Q · filed 2014-11-07 | 0.60% 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | 0.55% 10-Q · filed 2014-08-14 | 0.56% 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | 0.57% 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | 0.53% 10-K · filed 2014-03-31 | |||
| 2012-09-30 | 0.49% 10-Q · filed 2013-11-14 | 0.54% 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | 0.55% 10-Q · filed 2013-08-14 | 0.67% 10-Q · filed 2013-08-14 | ||
| 2012-03-31 | 0.82% 10-Q · filed 2013-05-13 | |||
| 2011-12-31 | 1.54% 10-K · filed 2013-03-29 | |||
| 2011-09-30 | 0.90% 10-Q · filed 2012-11-09 | 0.16% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 1.56% 10-Q · filed 2012-08-14 | 1.60% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |